<?xml version='1.0' encoding='utf-8'?>
<document id="25860376"><sentence text="Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan."><entity charOffset="85-95" id="DDI-PubMed.25860376.s1.e0" text="macitentan" /></sentence><sentence text="Pulmonary arterial hypertension (PAH) is a progressive disease of the lung vascular system, which leads to right-sided heart failure and ultimately death if untreated" /><sentence text=" Treatments to regulate the pulmonary vascular pressure target the prostacyclin, nitric oxide, and endothelin (ET) pathways"><entity charOffset="67-79" id="DDI-PubMed.25860376.s3.e0" text="prostacyclin" /><entity charOffset="81-93" id="DDI-PubMed.25860376.s3.e1" text="nitric oxide" /><pair ddi="false" e1="DDI-PubMed.25860376.s3.e0" e2="DDI-PubMed.25860376.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25860376.s3.e0" e2="DDI-PubMed.25860376.s3.e1" /></sentence><sentence text=" Macitentan, an oral, once-daily, dual ETA and ETB receptor antagonist with high affinity and sustained receptor binding is the first ET receptor antagonist to show significant reduction of the risk of morbidity and mortality in PAH patients in a large-scale phase III study with a long-term outcome"><entity charOffset="1-11" id="DDI-PubMed.25860376.s4.e0" text="Macitentan" /></sentence><sentence text=" Here we present a review of the available clinical pharmacokinetic, pharmacodynamic, pharmacokinetic/pharmacodynamic relationship, and drug-drug interaction data of macitentan in healthy subjects, patients with PAH, and in special populations"><entity charOffset="166-176" id="DDI-PubMed.25860376.s5.e0" text="macitentan" /><entity charOffset="212-215" id="DDI-PubMed.25860376.s5.e1" text="PAH" /><pair ddi="false" e1="DDI-PubMed.25860376.s5.e0" e2="DDI-PubMed.25860376.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25860376.s5.e0" e2="DDI-PubMed.25860376.s5.e1" /></sentence><sentence text=" " /></document>